Literature DB >> 16130936

Serrated adenoma of the colorectum and the DNA-methylator phenotype.

Jeremy R Jass1.   

Abstract

Serrated adenomas (SA) of the colorectum show features intermediate between hyperplastic polyps (HP) and adenomas. HP and SA are related lesions and there is now strong evidence for a 'serrated-polyp pathway' to colorectal cancer (CRC) that is largely independent of the classic adenoma-to-carcinoma sequence. A recently recognized lesion in this pathway is a HP variant characterized by relatively large size, atypical histology and proximal location in the colorectum. This HP variant has been given a variety of names in the literature including 'sessile SA' and 'type I SA'. Because this lesion lacks the traditional cytology of colorectal adenoma and in order to avoid confusion with SA, it is referred to in this review as sessile serrated polyp. SA are characterized by a heterogeneous group of changes at the molecular level, but a high proportion have BRAFmutations and DNA methylation. They may develop in HP or sessile serrated polyps, or may arise de novo. In the serratedpolyp pathway, the advent of genetic instability is likely to be an important rate-limiting step that drives rapid neoplastic evolution. Methylation and inactivation of the DNA repair genes MLH1 and MGMT (O-6-methylguanine-DNA methyltransferase) have been proposed as critical steps leading to genetic instability. Stretches of DNA rich in the bases guanine and cytosine (CpG islands; where p represents a phosphodiester bond linking adjacent cytosine and guanine bases) that are normally unmethylated may become methylated in malignant human colorectal tumors. Subsets of colorectal cancers with an unusually high number of methylated CpG islands have been described as having the 'CpG-island-methylator phenotype' It is possible that many, if not all, CRCs with the CpG-island-methylator phenotype evolve through the serrated-polyp pathway that would, therefore, explain approximately 20% of all CRCs. The current lack of guidelines for managing serrated polyps may explain the static incidence of proximal CRC, despite the falling incidence rates for left-sided CRC during the same time period.

Entities:  

Mesh:

Year:  2005        PMID: 16130936     DOI: 10.1038/ncponc0248

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  68 in total

Review 1.  Endoscopy and polyps-diagnostic and therapeutic advances in management.

Authors:  Scott R Steele; Eric K Johnson; Bradley Champagne; Brad Davis; Sang Lee; David Rivadeneira; Howard Ross; Dana A Hayden; Justin A Maykel
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

Review 2.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

Review 3.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

4.  Recommendations for the reporting of surgically resected specimens of colorectal carcinoma.

Authors:  Jeremy R Jass; Michael J O'Brien; Robert H Riddell; Dale C Snover
Journal:  Virchows Arch       Date:  2006-11-25       Impact factor: 4.064

Review 5.  Molecular classification and correlates in colorectal cancer.

Authors:  Shuji Ogino; Ajay Goel
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

6.  Nomenclature, molecular genetics and clinical significance of the precursor lesions in the serrated polyp pathway of colorectal carcinoma.

Authors:  John J Liang; Sadir Alrawi; Dongfeng Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

7.  New insights into the molecular pathogenesis of colorectal cancer.

Authors:  Kenneth E Hung; Daniel C Chung
Journal:  Drug Discov Today Dis Mech       Date:  2006

8.  Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.

Authors:  Takako Kawasaki; Katsuhiko Nosho; Mutsuko Ohnishi; Yuko Suemoto; Gregory J Kirkner; Reiko Dehari; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

9.  Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy.

Authors:  Patrick Chun; Zev A Wainberg
Journal:  Gastrointest Cancer Res       Date:  2009-09

10.  Genomic instability and carcinogenesis: an update.

Authors:  Wael M Abdel-Rahman
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.